Moderna produces Covid-19 shot targeting variant discovered in SA
The US biotech is preparing for a clinical trial to gauge the effectiveness of the vaccine on 501.V2 strain
Moderna has become the first vaccine maker to produce a Covid-19 shot targeted at the virus variant discovered in SA. It will ship the doses to the US National Institutes of Health (NIH) for a clinical trial.
The Boston-based biotech is taking a three-pronged strategy to address concerns that its vaccine, with several others, is less effective against the 501.V2 strain.
The company has already started giving previous trial participants a half-dose booster of the existing shot to top up their immune response. It has now created a vaccine booster targeted at the variant, also at half a dose. US immunologist Anthony Fauci’s team at the NIH will begin testing it in phase one trial participants within weeks. ..